Morgan Stanley’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.42M | Sell |
996,927
-294,089
| -23% | -$1.01M | ﹤0.01% | 4358 |
|
|
2025
Q1 | $2.88M | Buy |
1,291,016
+353,631
| +38% | +$789K | ﹤0.01% | 4360 |
|
|
2024
Q4 | $2.75M | Buy |
937,385
+347,732
| +59% | +$1.02M | ﹤0.01% | 4467 |
|
|
2024
Q3 | $1.53M | Buy |
589,653
+37,523
| +7% | +$97.6K | ﹤0.01% | 4798 |
|
|
2024
Q2 | $1.63M | Buy |
552,130
+161,991
| +42% | +$479K | ﹤0.01% | 4678 |
|
|
2024
Q1 | $1.77M | Sell |
390,139
-363,641
| -48% | -$1.65M | ﹤0.01% | 4665 |
|
|
2023
Q4 | $4.3M | Buy |
753,780
+172,365
| +30% | +$984K | ﹤0.01% | 4462 |
|
|
2023
Q3 | $2.67M | Sell |
581,415
-600,731
| -51% | -$2.76M | ﹤0.01% | 4198 |
|
|
2023
Q2 | $7.64M | Buy |
1,182,146
+272,742
| +30% | +$1.76M | ﹤0.01% | 3424 |
|
|
2023
Q1 | $6.86M | Buy |
909,404
+273,870
| +43% | +$2.06M | ﹤0.01% | 3498 |
|
|
2022
Q4 | $6.44M | Sell |
635,534
-67,476
| -10% | -$684K | ﹤0.01% | 3510 |
|
|
2022
Q3 | $6.95M | Buy |
703,010
+224,007
| +47% | +$2.21M | ﹤0.01% | 3353 |
|
|
2022
Q2 | $5.1M | Buy |
479,003
+85,867
| +22% | +$914K | ﹤0.01% | 3743 |
|
|
2022
Q1 | $3.83M | Sell |
393,136
-107,834
| -22% | -$1.05M | ﹤0.01% | 3965 |
|
|
2021
Q4 | $7.17M | Sell |
500,970
-235,049
| -32% | -$3.36M | ﹤0.01% | 3329 |
|
|
2021
Q3 | $14.8M | Buy |
736,019
+161,826
| +28% | +$3.24M | ﹤0.01% | 2427 |
|
|
2021
Q2 | $12.6M | Buy |
574,193
+501,828
| +693% | +$11M | ﹤0.01% | 2711 |
|
|
2021
Q1 | $2.46M | Buy |
72,365
+69,415
| +2,353% | +$2.36M | ﹤0.01% | 4102 |
|
|
2020
Q4 | $118K | Buy |
+2,950
| New | +$118K | ﹤0.01% | 5841 |
|